Paper Details
- Home
- Paper Details
Immunogenicity and Safety of Yellow Fever Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients After Withdrawal of Immunosuppressive Therapy.
Author: ArnaudCécile, BernaudinFrançoise, BoulayAude, CheminantMorgane, Colin de VerdièreNathalie, ConsignyPaul-Henri, KonopackiJohana, LapusanSimona, RobinChristine, Sicre de FontbruneFlore, SimonFrançois, SociéGérard, SuarezFelipe
Original Abstract of the Article :
As a live attenuated vaccine, yellow fever vaccine (YFV) is not routinely performed after allogeneic hematopoietic stem cell transplant (HSCT) despite it being the only efficient preventive therapy. We retrospectively identified 21 HSCT recipients immunized with YFV at a median of 39 months after HS...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1093/infdis/jix564
データ提供：米国国立医学図書館（NLM）
Yellow Fever Vaccine: A Safe and Effective Option for HSCT Recipients
Allogeneic hematopoietic stem cell transplantation (HSCT) is a life-saving procedure for individuals with certain blood disorders, but it often requires immunosuppressive therapy that can weaken the immune system. This research investigates the safety and immunogenicity of the yellow fever vaccine (YFV) in HSCT recipients after they have stopped immunosuppressive therapy. Imagine a desert ecosystem that has been disrupted by a drought, leaving the environment vulnerable. This research explores the potential of YFV to restore the immune system's strength in HSCT recipients who have undergone immunosuppression.
YFV: A Potential for Safe and Effective Immunization
The study demonstrates the safety and effectiveness of YFV in HSCT recipients after withdrawal of immunosuppression. It's like discovering a resilient plant in the desert that can thrive even after a period of drought. The findings provide valuable insights into the potential for safe and effective immunization strategies for HSCT recipients, helping to protect them from serious diseases like yellow fever.
Immunization after HSCT: A Pathway to Resilience
This research highlights the importance of immunizing HSCT recipients after they have stopped immunosuppressive therapy. It underscores the potential for restoring the immune system's strength and protecting individuals from infectious diseases. This research is a reminder that even after a period of vulnerability, the body's immune system can be strengthened and revitalized, offering a pathway to resilience.
Dr.Camel's Conclusion
This research delves into the world of HSCT and immunization, exploring the safety and effectiveness of YFV in HSCT recipients after withdrawal of immunosuppression. It's like discovering a hidden oasis of resilience in the desert of immunocompromised individuals, offering a path to restoring the immune system's strength and protecting them from infectious diseases.
Date :
- Date Completed 2019-04-12
- Date Revised 2019-04-12
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.